Cyclacel Pharmaceuticals, Inc.
(NASDAQ : CYCC)

( )
CYCC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.07%154.300.0%$1241.47m
AMGNAmgen, Inc. 0.00%249.951.3%$706.86m
SNSSSunesis Pharmaceuticals, Inc. 0.00%8.000.7%$559.23m
NVAXNovavax, Inc. -1.08%192.5580.0%$533.83m
ILMNIllumina, Inc. 0.00%403.153.5%$527.32m
GILDGilead Sciences, Inc. -0.03%64.871.0%$472.27m
REGNRegeneron Pharmaceuticals, Inc. 0.51%479.472.7%$433.31m
VRTXVertex Pharmaceuticals, Inc. 0.07%216.101.9%$372.34m
ALXNAlexion Pharmaceuticals, Inc. 0.00%153.732.0%$315.33m
BIIBBiogen, Inc. 0.00%266.191.7%$292.97m
BNTXBioNTech SE 0.59%130.410.0%$220.10m
EXASEXACT Sciences Corp. 1.48%129.8918.4%$197.74m
NBIXNeurocrine Biosciences, Inc. 0.00%92.974.9%$172.50m
CRSPCRISPR Therapeutics AG 0.52%121.510.6%$170.23m
OCGNOcugen, Inc. 1.79%6.830.0%$149.17m

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.